Author Archives: admin


Global Personalized Medicine Market Analysis (2016 to 2026) – Total Market Value is Expected to Reach $3.92 Trillion by 2026 – ResearchAndMarkets.com…

The "Global Personalized Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026 growing at a CAGR of 12.1% during the forecast period.

The efficient and advanced technology and Higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

Key Questions Answered in this Report:

Based on the End User, the hospital's segment is estimated to have a lucrative growth due to the lower cost personalized medicines availability in the hospitals.

As the practice of personalized medicine becomes more widespread, hospitals will also experience the need to adapt. That does not mean every hospital and medical centre should try and drive the science, but they should be open to collaborations to facilitate such work.

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Personalized Medicine Market, By Product

5.1 Introduction

5.2 Diagnostics

5.3 Personalized Medical Care

5.4 Personalized Nutrition & Wellness

5.5 Therapeutics

6 Global Personalized Medicine Market, By Technology

6.1 Introduction

6.2 Metabolomics

6.3 Pharmacodynamics

6.4 Pharmacogenetics

6.5 Pharmacogenomics

6.6 Pharmacokinetics

6.7 Pharmacoproteomics

6.8 Point-of-Care Testing

6.9 Stem Cell Therapy

7 Global Personalized Medicine Market, By Therapeutic Area

7.1 Introduction

7.2 Autoimmune Diseases

7.3 Blood Transfusion Safety

7.4 Cancer Management

7.5 Cardiovascular Diseases (CVD)

7.6 Central Nervous System (CNS) Disorders

7.7 Coagulation Therapy

7.8 Diabetes

7.9 Infectious Diseases

7.10 Antiviral

7.11 Neurology

7.12 Psychiatry

7.13 Oncology

7.14 Immunology

7.15 Respiratory

8 Global Personalized Medicine Market, By Distribution Channel

8.1 Introduction

8.2 Dietary Care Centers

8.3 Hospital's Pharmacies

8.4 Retail Pharmacies

8.5 Other Distribution Channels

9 Global Personalized Medicine Market, By Application

9.1 Introduction

9.2 Biomarker Identification

9.3 Clinical Research Applications

9.4 Companion Diagnostics

9.5 Health Informatics

10 Global Personalized Medicine Market, By End-User

10.1 Introduction

10.2 Academic Institutes

10.3 Bio and Health Informatics Companies

10.4 Clinical Care and Research Laboratories

10.5 Contract Research Organizations

10.6 Hospitals

10.7 Molecular Diagnostic Laboratories and Testing Facilities

10.8 Research Laboratories

10.9 Service Providers

10.10 Partner

10.11 Venture Capitalists

10.12 Other End Users

11 Global Personalized Medicine Market, By Geography

11.1 North America

11.2 Europe

11.3 Asia Pacific

11.4 South America

11.5 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape

13.1 Abbott Laboratories

13.2 Affymetrix Incorporated

13.3 Agendia N.V

13.4 Agilent Technologies, Inc

13.5 Amgen, Inc

13.6 Asuragen Incorporated

13.7 Bayer Healthcare Pharmaceuticals, Llc

13.8 Celera Diagnostics LLC

13.9 Celgene Corporation

13.10 Roche Diagnostics Corporation

13.11 Precision Biologics Incorporated

13.12 Siemens Healthcare Diagnostics, Inc

Read the original:
Global Personalized Medicine Market Analysis (2016 to 2026) - Total Market Value is Expected to Reach $3.92 Trillion by 2026 - ResearchAndMarkets.com...

Hyperbaric oxygen therapy can improve cardiac function in healthy, aging – The Jerusalem Post

Hyperbaric oxygen therapy (HBOT) can improve heart functionality in healthy aging humans, according to a study by the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center in Beer Yaacov.In this study, director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center Prof. Shai Efrati and Dr. Marina Leitman, head of the Echocardiography Unit and Noninvasive Cardiology Service at Shamir Medical Center, turned their attention to HBOTs impact on cardiac function.According to the center, the study of HBOT for cardiac function has been limited, mostly evaluating patients during and after short-term exposures. However, for the first time, the study was conducted in humans and it demonstrated that repetitive HBOT protocols have a sustained effect on heart function.Healthy patients receiving HBOT to improve cognitive function underwent a 60-session treatment course using the Sagol Centers regenerative HBOT protocols. Using a high-resolution echocardiography, 31 patients were evaluated before HBOT was administered and three weeks after treatment concluded to identify the sustained effect of the treatment.HBOT includes the inhalation of 100% oxygen at pressures exceeding one atmosphere absolute [ATA], which is the average atmospheric pressure exerted at sea level, in order to increase the amount of oxygen dissolved in the body tissues, Efrati told The Jerusalem Post.Efrati, who has been pioneering new approaches for the application of HBOT treatments that specifically focus on HBOTs ability to trigger regeneration in the body, said that in the past HBOT was used mostly to treat chronic non-healing wounds.In recent years, there is growing evidence on the regenerative effects of HBOT, he said. We have now realized that the combined action of both hyperoxia (an excess of oxygen in the body) and hyperbaric pressure, leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in improved mitochondrial metabolism with anti-apoptotic (anti-cell death) and anti-inflammatory effects.According to Efrati, the newly developed protocols used in this study, which includes the intermittent increasing and decreasing of oxygen concentration, induces what is known as the Hyperoxic Hypoxic Paradox.This, he said induces stem cells proliferation and mobilization, leading to the generation of new blood vessels (angiogenesis) and tissue regeneration.Efrati said that during the first studies they conducted at the Sagol Center, they evaluated the beneficial effects of HBOT in treating traumatic brain injury and stroke. However, in this study we evaluated for the first time the effect of these new regenerative HBOT protocols on the normal aging heart. For the first time in humans we have demonstrated that HBOT can improve cardiac function.Efrati said for the last 12 years his team has developed an ongoing research program that investigates the regenerative effects of HBOT on different issues and degrees of damage. At the beginning we were focused on non-healing peripheral wounds. Then, we turned our focus to certain types of brain injuries.However, once the researchers found that HBOT induced many of the essential elements crucial to repairing almost any mechanism, we initiated a complementary research program that targets other organs such as the heart and other elements related to expected age-related functional decline.Along with normal aging, there is typically a decrease in cardiac function particularly in the mitochondrial cells of the heart, Efrati said.The mitochondria are the powerhouse of the cell [and] this is where we create energy, he said. HBOTs ability to improve mitochondrial function may explain the beneficial effects that we saw in the cardiac function of this normal aging population.By exposing the mitochondria to the fluctuations in oxygen by the use of HBOT, the team observed an improvement in contractility function of the heart meaning, the heart muscle contracted more efficiency over the course of the 60-session protocol.Efrati said the effect was particularly evident in the left ventricle, which is the chamber responsible for pumping oxygenated blood to the rest of the body.This is only the beginning of our understanding of the impact of HBOT on cardiac function in a normally aging population, and a larger and more diverse cohort will be required to further evaluate our initial findings, he said.Asked whether this treatment could also be used on people who are predisposed to heart conditions, Efrati said the short answer is yes, but he stressed that more research is needed.As far as we know, we are the first to identify HBOTs ability to improve cardiac function, Efrati said. Our study was on a group of 31 asymptomatic normal aging heart patients.We believe it is important to expand the scope of this study to a larger group, with both symptomatic and asymptomatic patients to understand the possibilities for HBOT as a treatment for patients with heart-related diseases, he said.The Sagol Center has also been studying the impact of HBOT on a variety of cognitive conditions.We have also conducted studies which showed positive results for the treatment of post-concussion syndrome as a result of traumatic brain injury, post-stroke recovery, fibromyalgia, Efrati said, adding that today, medical professionals understand that fibromyalgia is linked to issues in the brain center responsible for pain interpretation.Not every patient will benefit from HBOT, which is why patient selection should be done very carefully based on the damage seen in brain imaging assessments, he said.For example, if someone has a stroke, some of the tissue at the core of the stroke will die we will not be able to recover this tissue, Efrati said. But, other tissue that is damaged but not fully dead... is where HBOT can help.This damaged tissue, known as the metabolic dysfunction tissue (penumbra), is where we can have an impact and help recover lost function, he said.On the time line as to when using HBOT protocols may be put into effect on healthy aging patients in Israel, Efrati said these studies are already ongoing.I cant speak too much about this, as we are in the process of developing the results of the first study for publication, he said. However, we believe HBOT can positively impact both cognitive and physical performance in aging adults based on what we have seen at this point.Efrati said they will continue pursuing this line of research as it has the ability to transform how we look at aging.A number of research collaborations are ongoing, including research on cognitive decline, fibromyalgia and PTSD, he said.In addition, we have an ongoing research program on athletic performance both in professional and amateur level athletes, which looks at how HBOT may further improve performance, he said. Finally, we are studying the impact of HBOT on healthy aging adults to understand how HBOT may improve our health and cognitive performance as we age.When you look at aging as a disease that can be measured, then it can be treated, and this is a serious area of investigation for us, Efrati said.The study, led by Dr. Marina Leitman, Dr. Shmuel Fuchs, Dr. Amir Hadanny, Dr. Zvi Vered and Efrati, was published in the International Journal of Cardiovascular Imaging.

Visit link:
Hyperbaric oxygen therapy can improve cardiac function in healthy, aging - The Jerusalem Post

Will Dialysis Become a Thing of the Past? – Jewish Link of New Jersey

By Ken Stephens | February 06, 2020

A groundbreaking study has shown that it is possible to rejuvenate damaged kidneys and improve their function, a procedure that could reverse chronic kidney disease, offsetting the need for dialysis. This is the first breakthrough in decades to combat this disease, often precipitated by hypertension and diabetes, and which affects a whopping 10% of the population worldwide.

The study was conducted by Professor Benjamin Dekel, head of Pediatric Nephrology and the Pediatric Stem Cell Research Institute in the Edmond and Lily Safra Childrens hospital at Sheba Medical Center, and published this week in the prestigious Cell Reports medical journal.

In past studies, researchers discovered that the adult kidney constantly renews itself over time through the activity of colonies of cells that replace lost and degenerated cells in the kidney. Prof. Dekel and his team have now developed an innovative technology that involves the extraction of such healthy kidney cells from diseased kidneys. These cells are then expanded into large numbers within a laboratory environment. By generation of three-dimensional cultures called kidney spheres, the cells show improved function to generate new kidney tissue and replace lost cells. The new cells are then reintroduced into the kidney where they rebuild it, positively influencing neighboring cells and improving its function (see diagram).

One of the most significant aspects of the discovery is that the newly developed technology uses the patients own cells, thereby circumventing the need for immunosuppression as well as problems associated with immune rejection.

Thus far, the method has been tested on mice, where the cells have shown their ability to generate new renal structures, associated with an ability to be retained for a long time once administered into the host kidney. The treated mice displayed improved renal function.

By focusing on improving and stabilizing renal function, this treatment has the potential to help millions of patients with chronic kidney disease and who have yet to require dialysis treatment.

These astounding results will be studied in clinical trials on patients with renal failure by the KidneyCure Bio firm, which commercialized this technology.

Prof. Benjamin Dekel, who led the project said, The breakthrough in this technology, which was developed at the Sheba Medical Center, is not only in the ability to maintain the kidney-renewing cells outside the body, but also in the ability to multiply them and generate large numbers of cells and make them function properly using the 3-D cultures. This is important news for patients with chronic kidney disease, who hopefully will benefit from these discoveries in the coming years. The ability to generate new kidney tissue (to replace the damaged tissue) could help millions of patients worldwide who suffer from kidney disease.

The trailblazing research was carried out by senior researchers Dr. Orit Harari-Steinberg, Dr. Dorit Omer, and Ms. Yehudit Gnatek from the Pediatric Stem Cell Research Institute, under the leadership of Prof. Dekel.

Collaborators include: Dr. Zohar Dotan, Head of Uro-Oncology Service from the urology department at Sheba Medical Center; Dr. Tomer Kalisky and co-workers from Bar Ilan University; and Prof. Yaron Fuchs and co-workers from The Technion.

By Ken Stephens

Link:
Will Dialysis Become a Thing of the Past? - Jewish Link of New Jersey

Global Gene Therapy Market to Cross USD 6892 Million By 2027 – TheInfobiz

Facts and Factors Market Researchhas published a new report titled Gene Therapy Market By Type (Germ Line Gene Therapy and Somatic Gene Therapy), By Vector Type (Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome), and By Therapy Area (Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2027.

According to the report, the globalgene therapy marketwas valued at approximately USD 919 million in 2018 and is expected to reach a value of around USD 6,892 million by 2027, at a CAGR of around 25.1% between 2019 and 2027.

Gene therapy is the kind of experimental method that makes use of genes for treating or preventing disease by inserting foreign genetic material like DNA or RNA into the persons cells. Scientists are studying gene therapy for treating various kinds of immuno-deficiencies, Parkinsons disease, HIV, and cancer by using myriad approaches. Today, many of the approaches to gene therapy are undergoing most intensive & rigorously testing. This includes replacing the mutated gene causing disease with the healthy gene copy. Another approach includes knocking out or inactivating a mutated gene operating improperly. Yet another approach includes a new gene into the body to combat the disease.

Request Free Sample Copy of Research Report @ https://www.fnfresearch.com/sample/gene-therapy-market-by-type-germ-line-gene

(The sample of this report is readily available on request).

This Free report sample includes:

New product approval & commercialization to drive the market trends

Between the periods from 2012 to 2018, nearly five single-use gene treatments received approval from the U.S. FDA for treating a rare form of genetic disorders. Moreover, gene treatments that have received approval are being tested by pharmaceutical firms in the market. Apart from this, current approvals of gene therapy products across the U.S., as well as European countries for treating a plethora of life-threatening diseases, are anticipated to steer the growth of gene therapy industry over the forecast timeline. Moreover, gene therapy can also be used for treating neurodegenerative disorders like Alzheimer, amyotrophic lateral sclerosis, and spinal muscular atrophy.

Furthermore, many of the reputed pharma firms like Bristol-Myers Squibb, BioMarin, and Pfizer are investing massively into the research activities pertaining to gene therapy. Apart from this, a rise in the occurrence of cancer is prompting the demand to treat the disease. Gene therapy is one of the key treatment kinds that will propel the market growth over the forecast period. However, inadequate reimbursement policies pertaining to the one-time gene treatments will downgrade market expansion.

In addition to this, conducting of randomized controlled trials can pose a threat to the expansion of the gene therapy industry as a result of the gene therapy features & projected patient population. Nevertheless, the ability of the gene therapy to eliminate the number of ailments with faulty or missing genes like hemophilia A will promote the market growth over the forecast period and thereby nullify the negative impact of hindrances on the business growth.

Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/gene-therapy-market-by-type-germ-line-gene

(You may enquire a report quote OR available discount offers to our sales team before purchase).

Somatic gene therapy to dominate the type segment

The growth of the segment over the forecast timeline is credited to the ability to treat the targeted cells in the patient population. The treatment is not passed to future generations and is restricted to only the patient who receives the somatic gene therapy. Moreover, it is used for treating a huge number of disorders like cystic fibrosis, cancer, and muscular dystrophy.

Cancer to lead the therapy area segment over the forecast period

The segmental expansion is attributed to a large number of pipeline drugs registered over the past few years along with increasing occurrence of cancer as a result of genetic changes.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/gene-therapy-market-by-type-germ-line-gene

(We customize your report according to your research need. Ask our sales team for report customization).

North America to dominate the overall regional market share during the forecast timespan

North American market, which accrued revenue of USD 380 million in 2018, is set to contribute majorly towards the overall market revenue by 2027. The regional market surge is credited to robust healthcare amenities, high per capita healthcare spending, and improvement in the reimbursement policies.

The key players included in this market are Advanced Cell & Gene Therapy, Audentes Therapeutics, Benitec Biopharma, Biogen, Blubird Bio, Inc., Bristol-Myers Squibb Company, CHIESI Farmaceutici SPA, Eurofins Scientific, Geneta Science, Genzyme Corporation, Gilead, GlaxoSmithKline PLC, Human Stem Cells institute, Novartis AG, Orchard Therapeutics, Pfizer Inc., Sangamo therapeutics, Spark therapeutics, and Voyager Therapeutics.

Browse detail report with in-depth TOC @ https://www.fnfresearch.com/gene-therapy-market-by-type-germ-line-gene

This report segments the gene therapy market as follows:

GlobalGene TherapyMarket:By TypeSegment Analysis

GlobalGene TherapyMarket: ByVector TypeSegment Analysis

GlobalGene TherapyMarket: ByTherapy AreaSegment Analysis

Global Gene TherapyMarket: Regional Segment Analysis

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,8 Century Avenue, Shanghai,Postal 200120, ChinaTel: +86 21 80360450

Email:sales@fnfresearch.com

Web:https://www.fnfresearch.com

See the original post here:
Global Gene Therapy Market to Cross USD 6892 Million By 2027 - TheInfobiz

Anemia: Causes, symptoms and treatment – Livescience.com

Anemia also known as iron-poor blood is a condition that develops when either the blood doesn't have enough red blood cells or the concentration of hemoglobin in red blood cells is very low. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen from the lungs to the rest of the body. When there are fewer red blood cells than normal or low levels of hemoglobin, the body doesn't get enough oxygen-rich blood for healthy functioning, which is what causes the symptoms of anemia.

Anemia is the most common blood disorder in the United States, affecting nearly 3 million Americans, according to the Centers for Disease Control and Prevention (CDC).

The term anemia is a broad one that represents several hundred different conditions some of them mild and treatable, others that are quite serious, said Dr. Nancy Berliner, chief of hematology at Brigham and Women's Hospital in Boston. There are three reasons that people are anemic, Berliner said: Either their body can't make enough red blood cells, something is destroying the red blood cells faster than their body can make news ones or blood loss (from menstrual periods, colon polyps or a stomach ulcer, for example) is greater than blood cell production.

There are more than 400 different types of anemia, according to the Pacific Heart, Lung & Blood Institute. Here are a few of the more common and better understood types:

Iron-deficiency anemia: The most common form of anemia is caused by low-iron levels in the body. Humans need iron to make hemoglobin, and most of that iron comes from dietary sources. Iron-deficiency anemia can result from a poor diet or from blood loss through menstruation, surgery or internal bleeding.

Pregnancy also increases the body's need for iron because more blood is needed to supply oxygen to the developing fetus, which may quickly drain the body's available iron stores, leading to a deficit. Problems absorbing iron from food because of Crohn's disease or celiac disease can also result in anemia.

Vitamin deficiency anemia: Besides iron, the body also needs two different B-vitamins folate and B12 to make enough red blood cells. Not consuming enough B12 or folate in the diet or an inability to absorb enough of these vitamins can lead to deficient red blood cell production.

Sickle cell anemia or sickle cell disease (SDC): This inherited disease causes red blood cells to become crescent-shaped rather than round. Abnormally shaped red cells can break apart easily and clog small blood vessels, resulting in a shortage of red blood cells and episodes of pain, according to the Mayo Clinic. People become chronically anemic because the sickle-shaped red cells are not pliable and can't get through blood vessels to deliver oxygen, Berliner said.

SDC occurs most often in people from parts of the world where malaria is or was common, according to the CDC; the sickle cell trait may provide protection against severe forms of malaria. In the U.S., SDC affects an estimated 100,000 Americans.

Thalassemia: Thalassemia is an inherited blood disorder that results in lower-than-normal levels of hemoglobin. This type of anemia is caused by genetic mutations in one or more of the genes that control the production of hemoglobin, according to the National Heart, Lung & Blood Institute (NHLBI).

Aplastic anemia: Aplastic anemia is a rare, life-threatening condition that develops when bone marrow stops making enough new blood cells, including red cells, white cells and platelets.

Aplastic anemia may be caused by radiation and chemotherapy treatments, which can damage stem cells in bone marrow that produce blood cells. Some medications, exposure to toxic chemicals like pesticides, viral infections and autoimmune disorders can also affect bone marrow and slow blood cell production.

Hemolytic anemias: This disorder causes red blood cells to be destroyed faster than bone marrow can replace them. Hemolytic anemias may be caused by infections, leaky heart valves, autoimmune disorders or inherited abnormalities in red blood cells, according to the American Society of Hematology.

Anemia of inflammation: Also called anemia of chronic disease, anemia of inflammation commonly occurs in people with chronic conditions that cause inflammation. This includes people with infections, rheumatoid arthritis, inflammatory bowel disease, chronic kidney disease, HIV/AIDS and certain cancers, according to the National Institute of Diabetes and Digestive and Kidney Diseases.

When a person has a disease or infection that causes inflammation, the immune system responds in a way that changes how the body works, resulting in anemia. For example, inflammation suppresses the availability of iron, so the body may not use and store the mineral normally for healthy red blood cell production, Berliner said. Inflammation may also stop the kidneys from producing a hormone that promotes red blood cell production.

The risk for anemia is higher in people with a poor diet, intestinal disorders, chronic diseases and infections. Women who are menstruating or pregnant are also prone to the disorder.

The risk of anemia increases with age, and about 10% to 12% of people over 65 are anemic, Berliner said. But the condition is not a normal part of aging, so the cause should be investigated when it's diagnosed, she said. Older adults may develop anemia from chronic diseases, such as cancer, or iron-deficiency anemia from abnormal bleeding.

According to NHLBI, the following types of people have an increased risk of developing anemia:

Mild forms of anemia may not cause any symptoms. When signs and symptoms of anemia do occur, they may include the following, according to the NHLBI:

The first test used to diagnose anemia is a complete blood count, which measures different parts and features of the blood: It shows the number and average size of red blood cells, as well as the amount of hemoglobin. A lower-than-normal red blood cell count or low levels of hemoglobin indicate anemia is present.

If more testing is needed to determine the type of anemia, a blood sample can be examined under a microscope to check for abnormalities in the size and shape of the red cells, white cells and platelets.

Related: This man's taste buds disappeared because of a blood condition

The treatment of anemia depends on the specific type of anemia, Berliner said, and anemias caused by nutritional deficiencies respond well to changes in diet. People with iron-deficiency anemia may need to take supplemental iron for several months or longer to replenish blood levels of the mineral. Some people, especially pregnant women, may find it hard to take iron because it causes side effects, such as an upset stomach or constipation, Berliner said.

For vitamin-deficiency anemias, treatment with B12 or folate from supplements (or a B12 shot) and foods, can improve levels of these nutrients in the blood, Berliner said.

Serious problems, such as aplastic anemia, which involves bone marrow failure, may be treated with medications and blood transfusions. Severe forms of thalassemia might need frequent blood transfusions.

Treatment for sickle cell anemia may include pain medications, blood transfusions or a bone marrow transplant.

Additional resources:

This article is for informational purposes only, and is not meant to offer medical advice.

Read this article:
Anemia: Causes, symptoms and treatment - Livescience.com

Here’s Why CRISPR Stocks Fell in January – The Motley Fool

Spurred by promising clinical results in an important trial, each of the three major CRISPR stocks had a great performance in the second half of 2019. Unfortunately, they didn't keep the momentum going in the first month of 2020.

Shares of Intellia Therapeutics (NASDAQ:NTLA) fell 18.8% in January, according to data provided by S&P Global Market Intelligence. That was followed by a 14.7% loss for shares of CRISPR Therapeutics (NASDAQ:CRSP) and a 10.7% tumble for shares of Editas Medicine (NASDAQ:EDIT).

While each has recovered some ground in the first week of February, this trio of pharma stocks is no stranger to volatility. Investors should probably expect that to continue as clinical programs advance in 2020.

Image source: Getty Images.

In November, CRISPR Therapeutics reported data for the first two individuals in the trial, one with sickle cell disease (SCD) and one with transfusion-dependent beta thalassemia (TDT), treated with its lead drug candidate CTX001. Both enjoyed significant benefits in their standard of living, which investors interpreted as a sign that CRISPR gene editing might actually live up to the hype.

That fueled annual gains of 113% for CRISPR Therapeutics last year. While Editas Medicine and Intellia Therapeutics gained only 30% and 7%, respectively, each had been sitting at a year-to-date loss in October.

What relevance does that have for the tumbles taken in January? First, it's not unusual for stocks to regress to the mean. Stocks that are red hot eventually cool off, while those that tumble without good reason eventually recover some ground.

Second, and the more important consideration for investors, is that the early stage results for CTX001 mean relatively little for the industry's pipeline of CRISPR-based gene editing drug candidates.

Consider that CTX001 is an ex vivo tool. Researchers harvest bone marrow from patients, extract specific types of stem cells, and engineer those with CTX001. The engineered stem cells are then grown in the lab before being reinjected into the patient.

Many other CRISPR-based drug candidates are designed as in vivo tools. That means the gene editing payloads are designed to engineer a patient's DNA while inside the body. An in vivo approach is inherently more complex and will be more difficult to control compared to an ex vivo approach.

Put another way, investors cannot take the promising, early stage results from CTX001 and extrapolate it broadly across all first-generation CRISPR tools. Wall Street certainly isn't, if the correlation between technical approach and stock performance is any guide.

Consider that the two most advanced drug candidates from CRISPR Therapeutics rely on ex vivo engineering. By contrast, the lead drug candidate from Editas Medicine relies on in vivo methods.

The lead pipeline asset from Intellia Therapeutics is also an in vivo tool, though unlike the lead assets from its peers, it has yet to advance to clinical trials.

Investors should expect 2020 to be a busy year for these CRISPR stocks. CRISPR Therapeutics will have more clinical data from CTX001 and the first set of data for its lead oncology asset CTX110.

Similarly, Editas Medicine should have results for EDIT101 and progress additional assets, while Intellia Therapeutics is preparing to finally enter the clinic with NTLA-2001 in the second half of the year.

Investors cannot know if the next batch of results will be as rosy as the initial data for CTX001, but they can probably expect another year of volatile stock movements.

See the article here:
Here's Why CRISPR Stocks Fell in January - The Motley Fool

Victoria Beckham says this product is the best product you will ever use – Marie Claire UK

Victoria Beckham is yet again busting out the big guns this time with hernew Cell Rejuvenating Power Serum.

Having combined forces with renowned stem cell researcher Augustinus Bader for a second time, the Cell Rejuvenating Power Serumsecures Beckhams position as the one to watch in the world of game-changing beauty.

Yesterday she took to instagram to declare, the science behind this is so incredible and I really notice a difference in my pore size and the fine lines around my eyes.

As if further proof were needed, Beckham posted a gorgeous video of her make-up free, luminous skin.

And shed be right. This serum is grounded in credible stem cell research by an unassuming scientist whos never attended a fashion show. In fact, Bader has spent the last 30 years at a medical clinic in Leipzig, Germany, treating burns victims.

Last November, Victoria Beckham Beauty launched its first skincare product, Cell Rejuvenating Priming Moisturiser, together with Bader. It incorporated his patented TFC8 technology. After using it, we now strongly believe that you need amino acids, vitamins and molecules that activate lazy stem cells to defend and repair the skin.

Youll find an even heftier dose of TFC8 in the Power Serum. It also reduces redness with niacinamide; protects againstpollution with antioxidant vitamin E and hydrates and strengthens with skin-quenching hyaluronic acid.

All the know-how is based upon scientific knowledge of what our skin cells really need to work at their best, says Bader.

Of course, this wouldnt be a Victoria Beckham Beauty product if the packaging didnt scream chic, too. Think frosted glass, simple black typography and a pipette to dispense just the right amount of serum every time.

But as well as looking good, the bottle does good, too. It is made of recyclable glass and can be disassembled so each piece enters the proper recycling stream.

If that wasnt enough to get your eco juices flowing, it is packaged in a 100% post-consumer waste carton and shipped in protective, biodegradable foam that can be dissolved under running water or disposed in compost. Pretty cool, no?

Made to be used before thePriming Moisturiser (or any other moisturiser youre using), you can also use the Cell Rejuvenating Power Serum in conjunction with Augustinus Baders cult The Cream or Rich Cream. Simply apply it first if you feel your skin needs extra cosseting.

Something tells us the Cell Rejuvenating Power Serum is yet another product Victoria Beckhams fans will instantly adore.

P.S. You had us at the selfie, VB.

View original post here:
Victoria Beckham says this product is the best product you will ever use - Marie Claire UK

How the next trip to the moon will get us ready for Mars – Deseret News

The following is a transcript from a recent interview conducted on KSL Newsradios Inside Sources, hosted by Deseret News opinion editor Boyd Matheson.

Boyd Matheson: Were very pleased today to be joined by the NASA Administrator Jim Bridenstine. Jim was nominated by President Donald Trump, confirmed by the Senate and sworn in as NASAs 13th administrator in April of 2018. Administrator Bridenstine was also previously elected to the United States Congress as a representative from Oklahomas 1st District, began his career in the U.S. Navy flying E2C Hawkeyes off the USS Abraham Lincoln aircraft carrier and has a host of other experience. Administrator Bridenstine, thanks so much for joining us today.

Jim Bridenstine: Its my honor. Thanks for having me.

BM: But we got to know each other a little bit back when you were in Congress. Im sure youre not missing those days today as opposed to being able to to play with all of the wonderful assets at NASA.

JB: Yeah, Ill tell you, it looks like the Hill is a really rough place to be right now. So Im very happy that Im at NASA.

Boyd Matheson: Well, its a great spot. Its a great spot for you. Many people have asked the question, you know, has NASA lost that ability to capture the imaginations of the American people? And I cant think of anyone better prepared to lead that effort than you.

JB: Well, I appreciate you saying that. I will tell you, there have been some pretty dark days at NASA going back about a decade. We had a moment there, where we retired the space shuttles. And then we canceled the replacement to the space shuttle, the Constellation program. And there was just a lot of a lot of concern about, What is the agency going to do? But were bringing it back and weve got some really big programs that are very close to completion now. And I will tell you with the president and the vice president giving us bigger budgets and bigger missions, with bipartisan support in the House and the Senate. I think our future is very bright and all of America will be very proud.

BM: Thats exciting to hear. And I and I want to dive into some of those programs and some of those initiatives moving forward and and maybe start with the Artemis program. I think thats probably one that should capture captured the nations attention. Tell us about that.

JB: Yeah, so we have a big agenda to go back to the moon. I like to say were going to go forward to the moon. I say forward because were going in a way thats never been done before. This time when we go to the moon, were going sustainably. In other words, were going to stay at the moon. Were going to learn how to live and work on another world for long periods of time. And were going to use the resources of the moon in order to live namely the water ice. When we think about the water ice, water ice represents water to drink, of course. It also represents air to breathe. And hydrogen and oxygen thats rocket fuel. Hydrogen and oxygen is the same rocket fuel that powered the space shuttles. And its available all over the south pole of the moon, were talking about hundreds of millions of tons of water ice on the south pole of the moon.

And of course, that was just discovered in 2009. So really, you know, 10 years ago, 11 years ago, this major discovery was made. And that should have instantaneously changed our space program. We should have immediately said, OK, were going to go back to the moon, were going to learn how to use the resources of the moon in order to live and work for long periods of time, and were going to take that knowledge. Were going to take that knowledge to Mars, and thats really what the Artemis program is all about. Its about a sustainable return to the moon. And then were going to take that knowledge and go to Mars. The thing its also important to remember is Artemis, in Greek mythology, is the twin sister of Apollo. And we loved the Apollo program. But remember, in the Apollo days, all of our astronauts came from fighter pilot backgrounds and test pilot backgrounds. And in those days, there were no opportunities for women.

Well, now we have this very diverse, highly qualified astronaut corps that includes women, and were going to go to the moon sustainably, with this very diverse astronaut corps under the name of Apollos twin sister, her name is Artemis. And she was in fact, the goddess of the moon. So I think its really an amazing story to share. You know, America has changed and the space program has changed. And I think its a good story that America can be proud of.

BM: Yeah, that is one that I think the American people can get behind, especially in a year like this where were celebrating womens suffrage and a host of other firsts and a lot of great advancements there as well.

So as you look at that Artemis program, you mentioned that it would be really the place where you would be sustainable and then be able to use that to parlay our way to Mars. Tell us a little bit more about that.

JB: So what we need to do is we need to learn how to live and work on another world for long periods of time. The challenge with Mars is that Mars and Earth are on the same side of the sun once every 26 months. So when you go to Mars, you have to be willing to stay for a couple of years. Were not talking about a couple of days, you have to go for a couple of years. Which means we have to use the resources of Mars to live and work for long periods of time. Well, the glory of the moon is that its always a three-day journey home. And so we can go to the moon, we can learn how to live and work on another world. We can prove the capabilities, build the technologies, utilize the water ice, as well as the regoliths and other minerals there on the on the surface of the moon. And then we know that if something goes wrong, we can always make it home. Which, of course, we proved that on Apollo 13, for example. Something went terribly wrong on the way to the moon, and our brave astronauts were able to make it home. Thats why the moon is so valuable. If we were to learn everything for the first time on Mars, the probability of success would go down, and so the moon really represents the best course for us to learn what is necessary to go to Mars. So, around the moon, were going to have in orbit what we call the (Lunar) Gateway.

The Gateway is a space station in orbit around the moon, and were already under contract to build the first elements of the Gateway, and that Gateway in orbit around the moon is going to give us access to the surface of the moon. Its maneuverable, it has solar electric propulsion, so it can make sure we can get to all parts of the moon. We learned in 2009, that theres hundreds of millions of tons of water ice on the south pole of the moon. Whats interesting is how come we didnt know that from 1969 all the way up until 2009? For 40 years, we missed the fact that there was water ice in hundreds of millions of tons, probably a lot more, on the south pole of the moon. Well, we missed it because we landed at the equatorial region six times with humans. We had 12 humans that landed on the moon six times, but they were all in the equatorial regions where there is no water ice. Well, what the Gateway enables us to do is because its maneuverable, it can go it can go to all the different orbits around the moon. And it can get us access to the north pole and the south pole. And we can go to where the resources are, and we can learn how to use those resources.

Well, that same Gateway is also evolvable. So it can be evolved to be the deep space transport that takes our first astronauts to Mars, for example. So it gives us capability and flexibility. At first, its going to be all about getting us access to the moon and being a command module for moon activities. But eventually, its going to take us all the way to Mars.

BM: Thats fantastic. I want to shift gears a little bit now and talk about some of the interesting components to me in terms of how we continue to sustain this. Obviously, theres private groups that are out there. So you know, some are questioning whats the role of the federal government now public-private partnerships there as well as the international connection. Obviously, were weve been reliant on our international allies and alliances as it relates to space for the last number of years. Give me a sense both in terms of continued role for NASA, from the federal government and the private sector, as well as our international component.

JB: Yeah, great question. So its another way that this time when we go to the moon, its entirely different than weve ever done before. We do have a very robust commercial marketplace. You know, people who listen to this maybe on the internet or however they listen to it, maybe they they have their internet from internet broadband from space, or maybe people have DirecTV or Dish Network or XM Radio. Theres all these space based communication capabilities that are transformational and remote-sensing capabilities that are transformational, but heres the point: The point is there is a very healthy and robust commercial marketplace for activities in space.

And so NASA has made a decision that instead of us purchasing, owning and operating all of the hardware to get things to space, what if we buy the services from this very robust commercial marketplace. So it goes from NASA. Were going from NASA purchasing, owning and operating the hardware to NASA becoming a customer, one customer of many customers. And when we do that, weve been doing it, for example, to resupply the International Space Station.

When we resupply the International Space Station, we buy a service, we dont purchase, own and operate our own rockets. And it has been very successful. Weve been very successful at driving down costs, which of course increases access. And were doing that now, in fact this year this is a big deal. This year were going to launch American astronauts on American rockets from American soil. And were doing it with a program that we call Commercial Crew. So where we are going to launch on in this case, weve got two providers. One is SpaceX with the Dragon Crew capsule, and the other is Boeing, with whats called the Starliner Crew capsule. And were buying services from these two countries to get our astronauts back and forth to the International Space Station.

The idea being that we want to be one customer of many customers. Were hoping that there is a very robust commercial marketplace that includes humans flying into space. And theres a lot of reasons to have humans in space. I can get into those in a few minutes. But when we think about commercial resupply of the International Space Station, commercial crew to the International Space Station, and now were going to start building commercial space stations, that will eventually be the replacements for the International Space Station. So theres a robust commercial marketplace where NASA can be a customer. And we can be one of many customers. And we can have numerous providers that are competing against each other on cost and innovation. The goal being that we need to drive down costs.

So were doing that already in low Earth orbit. Now what we need to do is we need to take that model all the way to the moon. So when we buy the lander that takes our astronauts to the surface of the moon, that lander is going to be a commercial lander, and we want to buy the service. Now make no mistake, were going to invest a lot in developing that capability. So it is a public-private partnership. But we want to have numerous providers that are competing against each other, driving down costs. But we want to do it as a service. And then again, we can be one customer of many with numerous providers that are driving down costs.

BM: Thats excellent. So I want to drill down. You mentioned getting more humans into space. And I want to attack that kind of in two tiers. One obviously, is just the regular consumer, the individuals out there, but then also as it relates to Space Force, and what that means from a military perspective as well.

JB: Yeah, so when we think about technologies that were proving right now on the International Space Station, we are proving that on the International Space Station, for example, we can we can compound pharmaceuticals in orbit around the Earth in a way that cannot be done in the gravity well of Earth. Were proving that we can create immunizations that cannot be created in the gravity well of Earth. We are proving that we can in fact, print in 3D human organs on the International Space Station using adult stem cells. So when we use adult stem cells to print human organs in 3D, what that means is that its going to have all of these technologies have amazing breakthrough capabilities for human life here on earth.

And that, of course, the goal being that will drive investment, private capital into the market to do more activities in space than ever before. So were using the International Space Station right now to create those markets.

But also, we think about people who have macular degeneration and they lose their eyesight. Were proving that we can create artificial retinas for the human eyeball in space in a way that you cannot create them on earth so that people who have macular degeneration dont have to lose their eyesight. And theres advanced materials like fiber-optic networks that can be created so pristinely in space that you dont have to have repeaters and of course, that drives down the cost of laying fiber-optic cables throughout, you know, cities. So theres advanced manufacturing, theres industrialized biomedicine. Theres all of these different capabilities that are being developed that can only be done in a zero gravity environment, they cannot be done on earth. And once these capabilities are proven, the goal would be that we would see lots of investment in space.

Now to your question about the Space Force. Remember why we have a navy. We have a Navy because there is commerce on the high seas, and without a navy, that commerce is vulnerable. And thats precisely why the United States of America is powerful, because we have an amazing economy with amazing free market enterprise. And then we also have the strength to back it up. The challenge with space is, as you can imagine, were already seeing, you know, its already a $400 billion market for commercial activities in space and its soon becoming a trillion dollar market. And there are nations out there like China, who have called space the American Achilles heel. Because of how dependent we are on space.

We think about the GPS constellation for navigation. It also is used for regulating flows of electricity on the power grid and regulating flows of data on wireless networks like the cellphone Im speaking on right now. Its also used for every banking transaction, a GPS timing signal is necessary. Without GPS, there is no banking. So we are dependent on space in a way that most Americans do not understand. And we want to grow this economy in space. And remember, the economy is on Earth, the activities are in space. But we want to grow it and in order to grow it countries around the world who believe they can bring America to its knees by destroying space, they need to understand that we are not going to let anybody get an advantage over the United States by threatening space.

NASA does not do Space Force. We are not a defense organization. NASA is a science and discovery organization. But Ill tell you, we are developing an economy and that economy is is put in jeopardy if we dont have security in space. And thats what the Space Force is all about.

BM: Thats fantastic. Just in our final few minutes here, Administrator Bridenstine. I just wanted you to talk to the American people in in general, you know. Theyve been listening to this for the last few minutes. What is it that you hope every American thinks about, what do you hope we do about our relationship to space and enter the future of the space program?

JB: Yeah, so I think the future of the space program is very bright. Were seeing bipartisan support in the House and in the Senate. Weve got strong support from the president. The president has put the vice president in charge of the National Space Council, of which I am a member. And so the amount of support were having right now, I dont think we have had this much support since the 1960s, when we had people on the moon, you know, in the early days, and of course, the early 1970s, as well.

So I think the space program is strong. I think its important for people to recognize how we are dependent on space in ways that most people dont know. And thats why its important for the American economy. Its important for national security. And these are the activities that we need to continue to grow. And of course, NASA plays strong. You mentioned international partners. Were growing our international partners.

Ill tell you, when we canceled the Constellation program and retired the space shuttles, a lot of our international partners were running for the hills because they thought America didnt have a vision. Well, now were bringing them all back. They all want to be with us on going to the moon. Theyve never been to the moon. Remember when we went to the moon last time it was America alone. This time when we go to the moon, were leading a coalition of nations. It puts the United States of America in the drivers seat to be the leader. But it also gives us access to more resources and capabilities.

And so this is an important program for the nation, for diplomacy, for economics, for national security. And I think its a point of pride and prestige for our nation. And so I would just encourage Americans out there who are listening, to know that your country is doing what it can to make sure that America leads and thats what were doing. Were leading.

BM: Fantastic. NASA Administrator Jim Bridenstine. Thank you so much for joining us. I appreciate your leadership of NASA and our space program and there are some very exciting things ahead that really will capture the imagination of the nation. Thanks so much for being with us today.

JB: Thank you, always. Will do it again.

Originally posted here:
How the next trip to the moon will get us ready for Mars - Deseret News

Biological robots, that is a thing now – 702

There are two stories I would like to tell with this edition of Business Unusual, the first is about the Darpa funded research to build robots out of living cells, the second is the incredible history of the animal that was used to build the first biological robots - Platannas.

The Defense Advanced Research Projects Agency (DARPA) is an agency of the American Department of Defense. It has funded many projects for military projects that in time have come to be used for civilian applications. The best-known example is the predecessor of the internet.

Why a military agency would fund research into creating living robots might be concerning but the stated objectives include managing environmental clean-ups or improving drug delivery which certainly are worthy pursuits. Of greater concern, are the ethical questions that are raised by creating new forms of a living organism. At the moment the designs dont attempt to make them self-replicating but that is part of the future plans.

Robots typically are designed and programmed to perform a specific task. Until now they would have been constructed out of non-living materials. These robots are also designed for a specific task but created from living cells. The choice of cell and the specific construction determines what action or function the living robot can perform.

One function that was attempted was movement. Starting from scratch researchers used stem cells from a frog to create skin cells and heart cells. The heart cells are muscles and so can contract while heart cells are able to do so rhythmically. Using those properties a machine learning program was tasked with testing thousands of configurations to determine which design would use the least cells to achieve the motion required. Once the best designs were determined, the living robots were constructed by researchers manipulating individual cells under a microscope.

The tiny constructed robots demonstrated that living robots designed by computer could offer an alternative to traditionally constructed machines. Future versions would look to make the constructions more complex and eventually able to self replicate.

One intended function was using a swarm of living robots with the ability to decompose plastic to be used to remove microplastics in the ocean. That may be a long way off, but if it is to become a reality the best time to start working on it is now.

Another application might be to not find plastic in the sea, but cancers in your body. Your body is already very good at doing so, but as we age and at certain times of our lives it becomes more challenging to correctly identify and kill cancer cells when they are still only tiny tumours.

This would require building robots consisting of your own body cells arranged in a way to allow them to move through the body and specifically find the corrupted cells. Adding them in numbers as we age may reduce the chance of developing tumours or even help the body recover after exposure to damaging external factors like sun damage to your skin.

This too is a long way off, but if successful and added to the many other options for extending and improving our lives then the research is most welcome.

_Image credit: Wikipedia African clawed frog_

Setting the other issues relating to building living robots aside, you might wonder why a frog from South Africa was chosen to build the first living robots.

It was not a random choice but points to a fascinating history that makes this particular frog one that has helped humanity overcome medical issues on a number of occasions.

A pregnancy test these days simply requires peeing on a stick. The reaction to a specific hormone in the urine can be isolated in minutes and let you know if you are pregnant within days of it occurring. It was not always this easy, the first method we are aware of would see a potentially pregnant woman urinate on ungerminated wheat and barley and wait a week or so to see if it germinated. Incredibly it works and was first mentioned over 3 000 years ago by the Egyptians. It was scientifically tested in the 1960s and found to be 70% accurate.

There were a variety of other methods used most on the expectation that something in the urine of females could be used to confirm pregnancy. In the 1920s it was injecting urine into female rabbits that after a day would require the examination of the rabbit ovaries. If swollen the woman was pregnant. In order to do the examination the rabbit was always killed and so the search continued for a better option.

Enter Lancelot Hogben, an English researcher lecturing in Cape Town in the early 1930s. He advised a student to consider using the local platanna as a potential for use as a model organism for biological tests. His hunch proved correct with Hillel Shapiro and Harry Zwarenstein creating the test to use the frog to indicate pregnancy.

The frog would be injected and in hours if the woman was pregnant would produce eggs. Not only was it accurate, but it also would not harm the frog which was easy to keep in a lab and would live for over a decade. As a result, the remarkable frog was exported around the globe and provided the answer to the question, am I pregnant, to the largest population explosion in our history. Most baby boomers parents and indeed many baby boomers would have found out if they were pregnant thanks to this strange-footed frog.

Xenopus literally means strange foot, frogs typically dont have claws which is why the African clawed frog got the name and as for Platanna, that may be a reference to the frog being very flat - plat in Afrikaans.

Given its widespread use for pregnancy and acceptance as a good species for embryonic development when researchers attempted to clone an organism, this frog was once again a key in understanding the process. In 1958, Xenopus was cloned not from splitting an embryonic cell which was the original method, but by using the DNA from an adult specialised cell which replaced the original DNA in a frog egg. The method proved successful and paved the way to allow Dolly the sheep to be cloned from an adult sheep cell in 1996.

We owe a huge debt of gratitude to six species that for a variety of reasons have helped us understand biological processes and how best to deal with disease and the efficacy of drugs. There are nematode worms, fruit flies, zebrafish, chickens, mice and the African clawed toad.

These six animals are our real guinea pigs.

Image credit: Xenobot - Tuft University & University of Vermont

View post:
Biological robots, that is a thing now - 702

Knocking Down Levels Of These Proteins Could Reverse Type 2 Diabetes – International Business Times

KEY POINTS

Type 2 diabetes has affected more than 30 million Americans till date.The condition usually occurs in individuals above the age of 45. But children, teens, and young adults are also developing it these days. Researchers have been finding ways to prevent and reverse the condition.

Researchers at Yale University have come up with a new way to reverse type 2 diabetes. They have identified a couple of proteins that could prevent diabetes when knocked down. According to the study, fasting switches on a certain process in the body in which the proteins TET3 and HNF4a increase in the liver and produces blood glucose. In type 2 diabetes patients, this switch fails to turn off after fasting.

Thus, they hypothesized that knocking down these two proteins could stop diabetes from developing.

In the Study published in cell reports, the researchers injected mice with genetic material called small interfering RNAs packaged inside viruses that target these two proteins. They found that insulin and blood glucose levels dropped significantly.

They also discovered that TET3 contributed to the development of liver fibrosis. They discovered that the protein TET3 plays a vital role in the fibrosis signaling pathway in three different locations acting as an important regulator in the development of liver fibrosis.

The findings of the study pave the way for opportunities in developing drugs that inhibit TET3 to slow or reverse fibrosis. Although liver fibrosis and type 2 diabetes are common conditions, there are very few treatment options currently.

Diabetes can lead to several other health conditions including stroke, kidney diseases, and heart diseases. Whereasliver fibrosis can lead to cirrhosis, which is one of the leading causes of death worldwide, according to the experts at Yale Liver Center.

Although there are drugs including metformin to control blood sugar levels in diabetic patients, they are subjected to a wide range of unpleasant side effects and moreover, patients consuming them can develop resistance to them.

While much is known about the role of TETs in development, stem cells, and cancer, little is known about their role in energy metabolism. In the current study we report an unexpected finding of P2 promoter reactivation in the adult liver by TET3 with an essential role in the control of hepatic glucose production (HGP), said the researchers.

diabetes symptoms shin spots Photo: stevepb - Pixabay

Follow this link:
Knocking Down Levels Of These Proteins Could Reverse Type 2 Diabetes - International Business Times